CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more


News and features about the latest developments in optics with a focus on industry

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Old vs new

Switching anti-VEGF drugs if a patient does not show a good response may not always be the best idea, study finds

AMD in an image of the back of the eye
New research is questioning the wisdom of switching anti-vascular endothelial growth factor (anti-VEGF) medications if a patient’s vision does not respond well to treatment in the first few months.

Clinicians treating patients with wet age-related macular degeneration or diabetic macular oedema with an anti-VEGF drug can commonly switch to another form if the person’s vision does not show improvement.

However, in a paper published in the journal JAMA Ophthalmology, US researchers wrote that, as yet, noone has looked at what happens if a patient continues with the original treatment past the point when a switch might be deemed appropriate.

To remedy this, the team analysed the data of patients treated with two anti-VEGF therapies, bevacizumab (Avastin) or ranibizumab (Lucentis), and selected a group of patients that met ‘switching criteria’ that the researchers had pre-determined.

Then, instead of being switched to an alternate medication, these patients continued with the same treatment. In the three months following the point at which they might have been switched, patients recorded a three- to five-letter improvement on visual acuity tests.

Central retinal thickness also showed improvement during this period, nearly doubling from an average 40 nanometres to 70 nanometres.

In their conclusion, the paper authors wrote that: “These results demonstrate the importance of having a comparison group to evaluate the effect of switching anti-VEGF agents for treatment.”